Kreitzer Anatol 4

What Happened Anatol Kreitzer, Chief Discovery Officer of MapLight Therapeutics (MPLT), sold a total of 45,422 shares in open-market transactions on April 27, 2026, generating total proceeds of roughly $1,347,067. The filing lists three disposition entries: 8,346 shares at a weighted-average price of $28.96 (≈ $241,700), 29,255 shares at $29.63 (≈ $866,826), and 7,821 shares at $30.50 (≈ $238,541). These were sales (S), not purchases, and thus represent share reductions rather than additional insider buys.

Key Details

• Transaction date: April 27, 2026 (reported on Form 4 filed April 29, 2026). Filing appears timely (no late filing indicated).
• Aggregate shares sold: 45,422; aggregate proceeds: ≈ $1,347,067.
• Per-row weighted-average prices and stated ranges:
  • 8,346 shares at $28.96 (sales occurred at prices in the $28.27–$29.26 range).
  • 29,255 shares at $29.63 (sales occurred at prices in the $29.27–$30.26 range).
  • 7,821 shares at $30.50 (sales occurred at prices in the $30.27–$30.64 range).
• Shares owned after transaction: Not provided in the data you supplied.
• Notable footnote: The filing states these transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 24, 2025. The filing also notes the reported prices are weighted averages and offers to provide a breakdown of the individual trade prices on request.

Context

• Trades executed under a 10b5-1 plan are prearranged and are commonly used by insiders to sell holdings on a pre-set schedule; such sales are generally treated as routine and do not necessarily signal a change in the insider’s view of the company.
• Because these are outright sales (code S), they reduce insider holdings; retail investors typically weigh purchases more heavily as a signal of insider confidence.